Amgen’s adjusted earnings per share reached $4.90, exceeding expectations and marking a 24% increase year-over-year.
Total revenues for Q1 2025 were $8.1 billion, a 9% increase from the previous year, driven by strong product demand.
Key drugs like Prolia and Xgeva outperformed sales expectations, with Prolia’s revenue hitting $1.1 billion, a 10% increase.
Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company known for its innovative therapies. It focuses on developing and manufacturing human therapeutics, with a strong portfolio of drugs targeting serious illnesses. Amgen competes with other biotech giants like Gilead Sciences and Biogen. On May 2, 2025, UBS updated its rating for Amgen to Neutral, maintaining a hold action, with the stock priced at approximately $278.63.
Amgen’s first-quarter 2025 results were impressive, surpassing both earnings and sales estimates. The company’s adjusted earnings per share reached $4.90, exceeding the Zacks Consensus Estimate of $4.16, marking a 24% increase from the previous year. This growth was driven by higher revenues, although partially offset by increased operating costs.
Total revenues for the quarter amounted to $8.1 billion, surpassing the expected $7.95 billion and reflecting a 9% year-over-year increase. Product revenues specifically rose by 11% to $7.87 billion, with a 14% increase in volumes, despite ongoing price declines. This indicates strong demand for Amgen’s products.
Key drugs such as Prolia, Xgeva, Repatha, Blincyto, and Evenity all exceeded sales expectations. Prolia, in particular, generated $1.1 billion in revenue, a 10% increase from the previous year, outperforming the Zacks Consensus Estimate of $994 million. This strong performance was attributed to higher volumes, which offset the impact of lower pricing.
Currently, Amgen’s stock price is $278.70, reflecting a decrease of 1.79% or $5.08. Today, the stock has traded as low as $275.20 and as high as $291.61. Over the past year, the stock has reached a high of $346.85 and a low of $253.30. Amgen’s market capitalization stands at approximately $149.84 billion, with a trading volume of 2,104,535 shares on the NASDAQ exchange.
